

U-M RESEARCH AWARD AND EXPENDITURES REPORT  
MARCH 2022

This report summarizes the overall trends in grant and contract activity across all three campuses of the University of Michigan through the first seven months of Fiscal Year 2022, which ended January 31.

Total research expenditures through the first seven months of FY22 totaled \$963 million, which is up 8.2 percent when compared to the first seven months of FY21.


The number of research submissions through the first seven months of FY22 was down 4.7 percent, and the value of those submissions decreased 10.6 percent when compared to January 2021.

The number of new research awards from external sponsors through the first seven months of FY22 increased 2.8 percent, but their value decreased 0.8 percent when compared to January 2021.

Rebecca Cunningham, Vice President for Research

Craig Reynolds, Assistant Vice President for Research-Sponsored Projects

## Expenditures




### Year to Date

FY20: \$972,571,086

FY21: \$890,587,620

FY22: \$963,372,185

## Submissions by Count




### Year to Date

FY20: 4,539

FY21: 4,459

FY22: 4,251

## Submissions by Amount




### Year to Date

FY20: \$3,893,938,600

FY21: \$3,617,647,316

FY22: \$3,233,145,645

## Awards by Count




### Year to Date

FY20: 1,686

FY21: 1,597

FY22: 1,641

## Awards by Amount



### Year to Date

FY20: \$898,548,368

FY21: \$962,154,325

FY22: \$954,117,751

# M | RESEARCH

## U-M RESEARCH AWARD AND EXPENDITURES REPORT MARCH 2022

### Top Monthly Awards

#### Industry

Principal Investigator	Department	Award Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
Burness, Monika	MM Int Med-Hematology/Oncology	A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with either HER2-Negative BRCA-Mutated or Triple-negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy	PPD Development, LP	\$7,477,779	4.9
Krauss, John	MM Int Med-Hematology/Oncology	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OFFIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUTCHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETYLEAD-IN OF ENCORAFENIB AND CETU..	Pfizer, Inc.	\$4,040,788	3.0
Kretzler, Matthias	MM Int Med-Nephrology	NEPTUNE Public-Private Partnership	Certa Therapeutics	\$2,295,000	5.0

#### Nonprofits

Principal Investigator	Department	Award Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
Kuo, Shih-Chen	MM Metabolism, Endo & Diabetes	Economic analysis of automated insulin delivery systems	Helmsley, The Leona M. and Harry B. Charitable	\$1,275,690	3.0
Niu, Wei	MM Neurology Department	Antisense oligonucleotide therapy of X-linked Protocadherin 19 related Autism and Epilepsy	Simons Foundation	\$995,167	3.0
Weiland, Christina	SOE-Educational Studies	How to Make the Most Out of Early Childhood Education: Lessons from Michigan's Transitional Kindergarten Program	Smith Richardson Foundation, Inc.	\$267,572	2.0

# Top Monthly Awards

## National Science Foundation

Principal Investigator	Department	Award Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
DeSantis, Morgan	LSA Molec./Cell./Develop. Bio	CAREER: Exploring the Functional Diversity of Cytoplasmic Dynein	National Science Foundation	\$1,530,496	5.0
Tibbetts, Elizabeth	LSA Ecology & Evolutionary Bio	Collaborative Research: Process and consequences of social partner choice revealed by multilayer network analysis	National Science Foundation	\$607,076	4.0
Liu, Allen	Mechanical Engineering	Collaborative Research: Mechanics of reconstituted self-organized contractile actomyosin systems	National Science Foundation	\$508,806	3.0

## National Institutes of Health

Principal Investigator	Department	Award Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
Ganesh, Santhi	MM Int Med-Cardiology	Genomic and Functional Studies of Dysplasia-Associated Arterial Diseases	Health and Human Services, Department of-National Institutes of Health	\$6,444,947	7.0
Singer, Ben	MM Int Med-Pulm./Critical Care	Enhancement of Brain Dysfunction in Sepsis Survivors by Alzheimer's Disease Neuropathology	Health and Human Services, Department of-National Institutes of Health	\$3,304,915	5.0
Shureiqi, Imad	MM Int Med-Hematology/Oncology	ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism	Health and Human Services, Department of-National Institutes of Health	\$3,273,591	5.0





U-M RESEARCH AWARD AND EXPENDITURES REPORT  
MARCH 2022

# Top Monthly Awards

## Department of Defense

Principal Investigator	Department	Award Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
Udager, Aaron	MM Ctr fr Translational Path.	Integrative molecular profiling of whole urine in African-American men with aggressive prostate cancer	Defense, Department of-Army, Department of the	\$900,875	3.0
Berenfeld, Omer	MM Int Med-Cardiology	Continuous, Portable, Non-Perfusion Based "Short Wave Assessment Tool" (SWAT) Improves Burn Care	Defense, Department of-Army, Department of the-Subcontracts	\$180,700	1.2